Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2024 Results Conference Call November 12, 2024 8:30 AM ET Company Participants Lisa Conte - Founder, President & Chief Executive Officer Pravin Chaturvedi - Chief Scientific Officer Carol Lizak - Chief Financial Officer Operator [Call Starts Abruptly] before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market ac ...

Exhibit 99.1 Jaguar Health Reports Third Quarter 2024 Financial Results The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 million Jaguar reported significant results in breast cancer patients in its phase 3 OnTarget trial for its cancer supportive care drug crofelemer; results in breast cancer patients accept ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 46-2956775 (Stat ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Lisa Conte - Founder, President & Chief Executive Officer Pravin Chaturvedi - Chief Scientific Officer Cathy Collis - Senior Vice President of Growth Strategy Carol Lizak - Chief Financial Officer Conference Call Participants Operator [Call starts abruptly] Before I turn the call over to the management, I would like to remind you that the management may make forward-looking statements relating ...

Exhibit 99.1 Jaguar Health Reports Second Quarter 2024 Financial Results The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus net Q2 2023 revenue of $2.67 million Company to complete analysis of full data for first and second 12-week periods of pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) in support of FDA d ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 46-2956775 (State or ...

Jaguar Health, Inc. (NASDAQ:JAGX) Special Conference Call July 23, 2024 8:30 AM ET Company Participants Lisa Conte - Founder, President & Chief Executive Officer Pravin Chaturvedi - Chief Scientific Officer & Chairman of Scientific Advisory Board Stacey Tinianov - Member of Napo's Scientific Advisory Board Allison Ackerman Shrier - Vice President of Medical Affairs & Clinical Research at Napo Pharmaceuticals Conference Call Participants Operator [Call starts abruptly] Before I turn the call over to manageme ...

Jaguar Health (NASDAQ:JAGX) stock is taking a beating on Tuesday after the commercial-stage pharmaceuticals company reported results from a Phase 3 clinical trial. The bad news for investors in JAGX shareholders is this clinical trial failing to meet its primary endpoint. The trial covered 10 different tumor types but crofelemer was only effective in patients with breast and respiratory cancers. "Clinical meaningfulness of these results is based on the information provided by solid tumor patients from a sur ...

Jaguar Health (NASDAQ:JAGX) stock is falling on Monday as the company prepares for a reverse stock split later this week. Jaguar Health is going to enact a one-for-60 reverse stock split on Thursday. That will see it consolidate 60 shares of JAGX stock into a single share. This will have the shares start trading on a split-adjusted basis when markets open that day. Jaguar Health notes that its shares will continue to trade on the Nasdaq Capital Market under the JAGX ticker post-split. However, the shares wi ...

And with that, I want to thank you all again. We're highly, highly energized about all the important near-term initiatives, including newly the upcoming launch of Gelclair and what is now imminent results from OnTarget for Cancer Therapy related Diarrhea Phase 3 Clinical Trial for Crofelemer. And this is a formulation that we currently have on the market Mytesi. Thank you all for the support of our mission to develop and commercialize prescription pharmaceuticals plant based for essential supportive care an ...